{
    "$schema": "https://github.com/Open-Systems-Pharmacology/QualificationPlan/releases/download/v3.3/OSP_Qualification_Plan_Schema.json",
    "Projects": [
        {
            "Id": "Midazolam",
            "Path": "../../Midazolam-Model.json",
            "BuildingBlocks": [],
            "SimulationParameters": [
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|Duodenum_int_Duodenum_cell|Midazolam|P (interstitial->intracellular)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|UpperJejunum_int_UpperJejunum_cell|Midazolam|P (interstitial->intracellular)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|LowerJejunum_int_LowerJejunum_cell|Midazolam|P (interstitial->intracellular)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|UpperIleum_int_UpperIleum_cell|Midazolam|P (interstitial->intracellular)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|LowerIleum_int_LowerIleum_cell|Midazolam|P (interstitial->intracellular)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|Caecum_int_Caecum_cell|Midazolam|P (interstitial->intracellular)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|ColonAscendens_int_ColonAscendens_cell|Midazolam|P (interstitial->intracellular)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|ColonTransversum_int_ColonTransversum_cell|Midazolam|P (interstitial->intracellular)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|ColonDescendens_int_ColonDescendens_cell|Midazolam|P (interstitial->intracellular)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|ColonSigmoid_int_ColonSigmoid_cell|Midazolam|P (interstitial->intracellular)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|Rectum_int_Rectum_cell|Midazolam|P (interstitial->intracellular)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|Duodenum_int_Duodenum_cell|Midazolam|P (intracellular->interstitial)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|UpperJejunum_int_UpperJejunum_cell|Midazolam|P (intracellular->interstitial)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|LowerJejunum_int_LowerJejunum_cell|Midazolam|P (intracellular->interstitial)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|UpperIleum_int_UpperIleum_cell|Midazolam|P (intracellular->interstitial)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|LowerIleum_int_LowerIleum_cell|Midazolam|P (intracellular->interstitial)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|Caecum_int_Caecum_cell|Midazolam|P (intracellular->interstitial)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|ColonAscendens_int_ColonAscendens_cell|Midazolam|P (intracellular->interstitial)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|ColonTransversum_int_ColonTransversum_cell|Midazolam|P (intracellular->interstitial)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|ColonDescendens_int_ColonDescendens_cell|Midazolam|P (intracellular->interstitial)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|ColonSigmoid_int_ColonSigmoid_cell|Midazolam|P (intracellular->interstitial)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                },
                {
                    "Project": "Midazolam",
                    "Simulation": "po 3 mg (solution)",
                    "Path": "Neighborhoods|Rectum_int_Rectum_cell|Midazolam|P (intracellular->interstitial)",
                    "TargetSimulations": [
                        "iv 0.001 mg (5 min)",
                        "iv 0.05 mg/kg (2 min)",
                        "iv 0.05 mg/kg (30 min)",
                        "iv 0.05 mg/kg (bolus)",
                        "iv 0.075 mg/kg (1 min)",
                        "iv 0.15 mg/kg (bolus)",
                        "iv 1 mg (2 min)",
                        "iv 1 mg (5 min)",
                        "iv 1 mg (bolus)",
                        "iv 2 mg (2 min)",
                        "iv 2 mg (bolus)",
                        "iv 5 mg (30 sec)",
                        "iv 5 mg (bolus)",
                        "po 0.003 mg (solution)",
                        "po 0.01 mg (solution)",
                        "po 0.075 mg (solution)",
                        "po 0.075 mg/kg (syrup)",
                        "po 1 mg (solution)",
                        "po 10 mg (solution)",
                        "po 10 mg (tablet)",
                        "po 15 mg (tablet)",
                        "po 15 mg (tablet) - with 1 h before high-fat breakfast",
                        "po 15 mg (tablet) - with 1h after high-fat breakfast",
                        "po 15 mg (tablet) - with high-fat breakfast",
                        "po 2 mg (solution)",
                        "po 2.5 mg (solution)",
                        "po 20 mg (tablet)",
                        "po 3.5 mg (solution)",
                        "po 4 mg (solution)",
                        "po 40 mg (tablet)",
                        "po 5 mg (solution)",
                        "po 6 mg (solution)",
                        "po 7.5 mg (solution)",
                        "po 7.5 mg (tablet)",
                        "po 8 mg (solution)",
                        "Mikus 2017"
                    ]
                }
            ]
        }
    ],
    "ObservedDataSets": [],
    "Plots": {
        "AxesSettings": {
            "GOFMergedPlotsPredictedVsObserved": [
                {
                    "Type": "X",
                    "Dimension": "Concentration (mass)",
                    "Unit": "µg/l",
                    "GridLines": false,
                    "Scaling": "Log"
                },
                {
                    "Type": "Y",
                    "Dimension": "Concentration (mass)",
                    "Unit": "µg/l",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ],
            "GOFMergedPlotsResidualsOverTime": [
                {
                    "Type": "X",
                    "Dimension": "Time",
                    "Unit": "h",
                    "GridLines": false,
                    "Scaling": "Linear"
                },
                {
                    "Type": "Y",
                    "Dimension": "Dimensionless",
                    "Unit": "",
                    "GridLines": false,
                    "Scaling": "Linear"
                }
            ],
            "ComparisonTimeProfile": [
                {
                    "Type": "X",
                    "Dimension": "Time",
                    "Unit": "h",
                    "GridLines": false,
                    "Scaling": "Linear"
                },
                {
                    "Type": "Y",
                    "Dimension": "Concentration (mass)",
                    "Unit": "µg/l",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ],
            "DDIRatioPlotsPredictedVsObserved": [
                {
                    "Type": "X",
                    "Dimension": "Dimensionless",
                    "Unit": "",
                    "GridLines": false,
                    "Scaling": "Log"
                },
                {
                    "Type": "Y",
                    "Dimension": "Dimensionless",
                    "Unit": "",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ],
            "DDIRatioPlotsResidualsVsObserved": [
                {
                    "Type": "X",
                    "Dimension": "Dimensionless",
                    "Unit": "",
                    "GridLines": false,
                    "Scaling": "Log"
                },
                {
                    "Type": "Y",
                    "Dimension": "Dimensionless",
                    "Unit": "",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ],
            "PKRatioPlots": [
                {
                    "Type": "X",
                    "Dimension": "Age",
                    "Unit": "year(s)",
                    "GridLines": false,
                    "Scaling": "Linear"
                },
                {
                    "Type": "Y",
                    "Dimension": "Dimensionless",
                    "Unit": "",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ]
        },
        "PlotSettings": {
            "ChartWidth": 500,
            "ChartHeight": 400,
            "Fonts": {
                "AxisSize": 11,
                "LegendSize": 9,
                "OriginSize": 9,
                "FontFamilyName": "Arial",
                "WatermarkSize": 40
            }
        },
        "AllPlots": [
            {
                "SectionReference": "model-building",
                "Project": "Midazolam",
                "Simulation": "iv 0.001 mg (5 min)"
            },
            {
                "SectionReference": "model-building",
                "Project": "Midazolam",
                "Simulation": "iv 1 mg (5 min)"
            },
            {
                "SectionReference": "model-building",
                "Project": "Midazolam",
                "Simulation": "po 0.003 mg (solution)"
            },
            {
                "SectionReference": "model-building",
                "Project": "Midazolam",
                "Simulation": "po 3 mg (solution)"
            },
            {
                "SectionReference": "model-building",
                "Project": "Midazolam",
                "Simulation": "po 7.5 mg (tablet)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "iv 0.05 mg/kg (2 min)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "iv 0.05 mg/kg (30 min)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "iv 0.05 mg/kg (bolus)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "iv 0.075 mg/kg (1 min)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "iv 0.15 mg/kg (bolus)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "iv 1 mg (2 min)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "iv 1 mg (bolus)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "iv 2 mg (2 min)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "iv 2 mg (bolus)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "iv 5 mg (30 sec)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "iv 5 mg (bolus)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "Mikus 2017"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 0.01 mg (solution)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 0.075 mg (solution)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 0.075 mg/kg (syrup)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 1 mg (solution)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 10 mg (solution)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 10 mg (tablet)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 15 mg (tablet)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 15 mg (tablet) - with 1h after high-fat breakfast"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 2 mg (solution)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 20 mg (tablet)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 3.5 mg (solution)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 4 mg (solution)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 40 mg (tablet)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 5 mg (solution)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 6 mg (solution)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 7.5 mg (solution)"
            },
            {
                "SectionReference": "model-verification",
                "Project": "Midazolam",
                "Simulation": "po 8 mg (solution)"
            }
        ],
        "GOFMergedPlots": [
            {
                "Title": "Midazolam concentration in plasma/blood",
                "SectionReference": "diagnostics-plots",
                "Artifacts": [
                    "Plot",
                    "GMFE",
                    "Measure"
                ],
                "PlotTypes": [
                    "predictedVsObserved",
                    "residualsOverTime"
                ],
                "Groups": [
                    {
                        "Caption": "Intravenous administration (model building)",
                        "Symbol": "Triangle",
                        "OutputMappings": [
                            {
                                "Project": "Midazolam",
                                "Simulation": "iv 0.001 mg (5 min)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Hohmann 2015 - iv 0.001 mg - Midazolam - IV - 0.001 mg - Plasma - agg. (n=16)",
                                "Color": "#2166ac"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "iv 1 mg (bolus)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Kharasch 2004 - iv Control (Perpetrator Placebo) - Midazolam - IV - 1 mg - Plasma - agg. (n=10)",
                                "Color": "#2166ac"
                            }
                        ]
                    },
                    {
                        "Caption": "Oral administration, solution (model building)",
                        "Symbol": "Circle",
                        "OutputMappings": [
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 0.003 mg (solution)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Hohmann 2015 - po 0.003 mg - Midazolam - PO - 0.003 mg - Plasma - agg. (n=16)",
                                "Color": "#2166ac"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 3 mg (solution)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Hohmann 2015 - po 3 mg - Midazolam - PO - 3 mg - Plasma - agg. (n=16)",
                                "Color": "#2166ac"
                            }
                        ]
                    },
                    {
                        "Caption": "Oral administration, tablet (model building)",
                        "Symbol": "Square",
                        "OutputMappings": [
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 7.5 mg (tablet)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Link 2008 - po Control (Perpetrator Placebo) - Midazolam - PO - 7.5 mg - Plasma - agg. (n=8)",
                                    "Olkkola 1994 - po Control (Perpetrator Placebo) - Midazolam - PO - 7.5 mg - Plasma - agg. (n=9)",
                                    "Olkkola 1996 - day 1 (po) Control (Perpetrator Placebo) - Midazolam - PO - 7.5 mg - Plasma - agg. (n=12)",
                                    "Olkkola 1996 - day 6 (po) Control (Perpetrator Placebo) - Midazolam - PO - 7.5 mg - Plasma - agg. (n=12)",
                                    "Saari 2006 - po Control (Perpetrator Placebo) - Midazolam - PO - 7.5 mg - Plasma - agg. (n=10)",
                                    "Ahonen 1995 - Control (Perpetrator Placebo) - Midazolam - PO - 7.5 mg - Plasma - agg. (n=12)"
                                ],
                                "Color": "#2166ac"
                            }
                        ]
                    },
                    {
                        "Caption": "Intravenous administration (model verification)",
                        "Symbol": "Triangle",
                        "OutputMappings": [
                            {
                                "Project": "Midazolam",
                                "Simulation": "iv 0.05 mg/kg (2 min)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Olkkola 1993 - iv Control (Perpetrator Placebo) - Midazolam - IV - 0.05 mg/kg - Plasma - agg. (n=6)",
                                    "Saari 2006 - iv Control (Perpetrator Placebo) - Midazolam - IV - 0.05 mg/kg - Plasma - agg. (n=10)",
                                    "Olkkola 1996 - day 4 (iv) Control (Perpetrator Placebo) - Midazolam - IV - 0.05 mg/kg - Plasma - agg. (n=12)"
                                ],
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "iv 0.05 mg/kg (30 min)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Whole Blood (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Gorski 1998 - iv Control (Perpetrator Placebo) - Midazolam - IV - 0.05 mg/kg - Whole Blood - agg. (n=16)",
                                    "Gorski 2003 - iv Control (Perpetrator Placebo) - Midazolam - IV - 0.05 mg/kg - Whole Blood - agg. (n=52)",
                                    "Quinney 2008 - Control iv Midazolam All - Midazolam - IV - 0.05 mg/kg - Whole Blood - agg. (n=16)"
                                ],
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "iv 0.05 mg/kg (bolus)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Szalat 2007 - Control (Perpetrator Placebo) - Midazolam - IV - 0.05 mg/kg - Plasma - agg. (n=3)",
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "iv 0.075 mg/kg (1 min)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Swart 2002 - day 5 Control (Perpetrator Placebo) - Midazolam - IV - 0.075 mg/kg - Plasma - agg. (n=8)",
                                    "Allonen 1981 - iv - Midazolam - IV - 0.075 mg/kg - Plasma - agg. (n=6)"
                                ],
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "iv 0.15 mg/kg (bolus)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Heizmann 1983 - iv 0.15 mg/kg - Indiv. A.St. - Midazolam - IV - 0.15 mg/kg - Plasma - indiv.",
                                    "Heizmann 1983 - iv 0.15 mg/kg - Indiv. CH.B. - Midazolam - IV - 0.15 mg/kg - Plasma - indiv.",
                                    "Heizmann 1983 - iv 0.15 mg/kg - Indiv. E.Sch. - Midazolam - IV - 0.15 mg/kg - Plasma - indiv.",
                                    "Heizmann 1983 - iv 0.15 mg/kg - Indiv. K.M. - Midazolam - IV - 0.15 mg/kg - Plasma - indiv.",
                                    "Heizmann 1983 - iv 0.15 mg/kg - Indiv. O.A. - Midazolam - IV - 0.15 mg/kg - Plasma - indiv.",
                                    "Heizmann 1983 - iv 0.15 mg/kg - Indiv. R.H. - Midazolam - IV - 0.15 mg/kg - Plasma - indiv."
                                ],
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "iv 1 mg (2 min)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Yu 2004 - Control CYP3A5*3/*3 - Midazolam - IV - 1 mg - Plasma - agg. (n=7)",
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "iv 1 mg (5 min)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Hohmann 2015 - iv 1 mg - Midazolam - IV - 1 mg - Plasma - agg. (n=16)",
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "iv 1 mg (bolus)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Phimmasone 2001 - Control (Perpetrator Placebo) - Midazolam - IV - 1 mg - Plasma - agg. (n=6)",
                                    "Kharasch 1997 - Control (Perpetrator Placebo) - Midazolam - IV - 1 mg - Plasma - typical (n=9)",
                                    "Kharasch 2011 - iv Control (Perpetrator Placebo) - Midazolam - IV - 1 mg - Plasma - agg. (n=12)",
                                    "Shin 2013 - Control phase (Midazolam alone) - Midazolam - IV - 1 mg - Plasma - agg. (n=24)",
                                    "Shin 2016 - Midazolam alone - Midazolam - IV - 1 mg - Plasma - agg. (n=12)"
                                ],
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "iv 2 mg (bolus)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Link 2008 - iv Control (Perpetrator Placebo) - Midazolam - IV - 2 mg - Plasma - agg. (n=8)",
                                    "Darwish 2008 - iv - Midazolam - IV - 2 mg - Plasma - agg. (n=24)"
                                ],
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "iv 2 mg (2 min)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Majumdar 2007 - po Control (Perpetrator Placebo) - Midazolam - IV - 2 mg - Plasma - agg. (n=12)",
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "iv 5 mg (30 sec)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Schwagmeier 1998 - iv administration - Midazolam - IV - 5 mg - Plasma - agg. (n=8)",
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "iv 5 mg (bolus)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Smith 1981 - iv 5 mg - Midazolam - IV - 5 mg - Plasma - agg. (n=6)",
                                "Color": "#b2182b"
                            }
                        ]
                    },
                    {
                        "Caption": "Oral administration, solution (model verification)",
                        "Symbol": "Circle",
                        "OutputMappings": [
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 0.075 mg (solution)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Eap 2004 - 0.075 mg Control (Perpetrator Placebo) - Midazolam - PO - 0.075 mg - Plasma - agg. (n=21)",
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 0.075 mg/kg (syrup)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Chung 2006 - Control (Perpetrator Placebo) - Midazolam - PO - 0.075 mg/kg - Plasma - agg. (n=18)",
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 5 mg (solution)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Darwish 2008 - oral - Midazolam - PO - 5 mg - Plasma - agg. (n=24)",
                                    "Okudaira 2007 - EM 0 Control (Perpetrator Placebo) - Midazolam - PO - 5 mg - Plasma - agg. (n=12)"
                                ],
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 6 mg (solution)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Greenblat 2003 - Control (Perpetrator Placebo) - Midazolam - PO - 6 mg - Plasma - agg. (n=25)",
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 3 mg (solution)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Kharasch 2004 - po #1 Control (Perpetrator Placebo) - Midazolam - PO - 3 mg - Plasma - agg. (n=10)",
                                    "Katzenmaier 2010 - Midazolam control - Midazolam - PO - 3 mg - Plasma - agg. (n=12)",
                                    "Kharasch 2011 - po Control (Perpetrator Placebo) - Midazolam - PO - 3 mg - Plasma - agg. (n=12)",
                                    "Markert 2013 - Control (Perpetrator Placebo) - Midazolam - PO - 3 mg - Plasma - agg. (n=11)"
                                ],
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 3.5 mg (solution)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Whole Blood (Peripheral Venous Blood)",
                                "ObservedData": "Quinney 2008 - Control po Midazolam All - Midazolam - PO - 3.0 - 4.0 mg - Whole Blood - agg. (n=16)",
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 4 mg (solution)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Whole Blood (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Gorski 2003 - po Control (Perpetrator Placebo) - Midazolam - PO - 4 mg - Whole Blood - agg. (n=52)",
                                    "Gorski 1998 - po Control (Perpetrator Placebo) - Midazolam - PO - 4 mg - Whole Blood - agg. (n=16)"
                                ],
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 0.01 mg (solution)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Prueksaritanont 2017 - Midazolam in microdosecocktail alone - Midazolam - PO - 10 µg - Plasma - agg. (n=12)",
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 1 mg (solution)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "van Dyk 2018 - Midazolam in Caucasian at baseline - Midazolam - PO - 1 mg - Plasma - agg. (n=19)",
                                    "Wiesinger 2020 - Control phase (no RIF) - Midazolam - PO - 1 mg - Plasma - agg. (n=65)",
                                    "Chattopadhyay 2018 - Control (without Rifampicin) - Midazolam - PO - 1 mg - Plasma - agg. (n=11)"
                                ],
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 7.5 mg (solution)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Eap 2004 - 7.5 mg Control (Perpetrator Placebo) - Midazolam - PO - 7.5 mg - Plasma - agg. (n=13)",
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 8 mg (solution)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Gurley 2008a - Control pre-Kava kava (Perpetrator Placebo) - Midazolam - PO - 8 mg - Plasma - agg. (n=16)",
                                    "Gurley 2008a - Control pre-Goldenseal (Perpetrator Placebo) - Midazolam - PO - 8 mg - Plasma - agg. (n=16)",
                                    "Gurley 2008a - Control pre-Clarithromycin (Perpetrator Placebo) - Midazolam - PO - 8 mg - Plasma - agg. (n=16)",
                                    "Gurley 2008a - Control pre-Rifampicin (Perpetrator Placebo) - Midazolam - PO - 8 mg - Plasma - agg. (n=16)",
                                    "Gurley 2006 - Control pre-Milk thistle (Perpetrator Placebo) - Midazolam - PO - 8 mg - Plasma - agg. (n=19)",
                                    "Gurley 2006 - Control pre-Black cohosh (Perpetrator Placebo) - Midazolam - PO - 8 mg - Plasma - agg. (n=19)",
                                    "Gurley 2006 - Control pre-Clarithromycin (Perpetrator Placebo) - Midazolam - PO - 8 mg - Plasma - agg. (n=19)",
                                    "Gurley 2006 - Control pre-Rifampicin (Perpetrator Placebo) - Midazolam - PO - 8 mg - Plasma - agg. (n=19)"
                                ],
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 10 mg (solution)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Smith 1981 - oral solution 10 mg - Midazolam - PO - 10 mg - Plasma - agg. (n=6)",
                                    "Lam 2003 - Midazolam before Fluvoxamine - Midazolam - PO - 10 mg - Plasma - agg. (n=10)",
                                    "Lam 2003 - Midazolam before Ketoconazole - Midazolam - PO - 10 mg - Plasma - agg. (n=10)"
                                ],
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 2 mg (solution)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Lutz 2018 - Cohort 1, Control - Midazolam - PO - 2 mg - Plasma - agg. (n=20)",
                                    "Lutz 2018 - Cohort 2, Control - Midazolam - PO - 2 mg - Plasma - agg. (n=20)"
                                ],
                                "Color": "#b2182b"
                            }
                        ]
                    },
                    {
                        "Caption": "Oral administration, tablet (model verification)",
                        "Symbol": "Square",
                        "OutputMappings": [
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 10 mg (tablet)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Heizmann 1983 - po 10 mg - Indiv. R.H. - Midazolam - PO - 10 mg - Plasma - indiv.",
                                    "Heizmann 1983 - po 10 mg - Indiv. O.A. - Midazolam - PO - 10 mg - Plasma - indiv.",
                                    "Heizmann 1983 - po 10 mg - Indiv. K.M. - Midazolam - PO - 10 mg - Plasma - indiv.",
                                    "Smith 1981 - oral tablet 10 mg - Midazolam - PO - 10 mg - Plasma - agg. (n=6)"
                                ],
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 15 mg (tablet)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Bornemann 1986 - fasting condition - Midazolam - PO - 15 mg - Plasma - agg. (n=18)",
                                    "Backman 1994 - Midazolam with placebo - Midazolam - PO - 15 mg - Plasma - agg. (n=9)",
                                    "Backman 1996 - Control (Perpetrator Placebo) - Midazolam - PO - 15 mg - Plasma - agg. (n=10)",
                                    "Backman 1998 - Phase I (Control (Perpetrator Placebo)) - Midazolam - PO - 15 mg - Plasma - agg. (n=9)",
                                    "Olkkola 1993 - po Control (Perpetrator Placebo) - Midazolam - PO - 15 mg - Plasma - agg. (n=12)",
                                    "Yeates 1996 - Control (Perpetrator Placebo) - Midazolam - PO - 15 mg - Plasma - agg. (n=12)",
                                    "Zimmermann 1996 - Control (Perpetrator Placebo) - Midazolam - PO - 15 mg - Plasma - agg. (n=12)",
                                    "Allonen 1981 - oral - Midazolam - PO - 15 mg - Plasma - agg. (n=6)"
                                ],
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 2 mg (solution)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Templeton 2010 - Control (Perpetrator Placebo) - Midazolam - PO - 2 mg - Plasma - agg. (n=6)",
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 20 mg (tablet)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Heizmann 1983 - po 20 mg - Indiv. R.H. - Midazolam - PO - 20 mg - Plasma - indiv.",
                                    "Heizmann 1983 - po 20 mg - Indiv. O.A. - Midazolam - PO - 20 mg - Plasma - indiv.",
                                    "Heizmann 1983 - po 20 mg - Indiv. K.M. - Midazolam - PO - 20 mg - Plasma - indiv.",
                                    "Heizmann 1983 - po 20 mg - Indiv. E.Sch. - Midazolam - PO - 20 mg - Plasma - indiv.",
                                    "Heizmann 1983 - po 20 mg - Indiv. CH.B. - Midazolam - PO - 20 mg - Plasma - indiv.",
                                    "Heizmann 1983 - po 20 mg - Indiv. A.St. - Midazolam - PO - 20 mg - Plasma - indiv."
                                ],
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 40 mg (tablet)",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Heizmann 1983 - po 40 mg - Indiv. E.Sch. - Midazolam - PO - 40 mg - Plasma - indiv.",
                                    "Heizmann 1983 - po 40 mg - Indiv. CH.B. - Midazolam - PO - 40 mg - Plasma - indiv.",
                                    "Heizmann 1983 - po 40 mg - Indiv. A.St. - Midazolam - PO - 40 mg - Plasma - indiv."
                                ],
                                "Color": "#b2182b"
                            },
                            {
                                "Project": "Midazolam",
                                "Simulation": "po 15 mg (tablet) - with 1h after high-fat breakfast",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Bornemann 1986 - 1 h after a meal - Midazolam - PO - 15 mg - Plasma - agg. (n=18)",
                                "Color": "#b2182b"
                            }
                        ]
                    },
                    {
                        "Caption": "Mixed applications",
                        "Symbol": "Circle",
                        "OutputMappings": [
                            {
                                "Project": "Midazolam",
                                "Simulation": "Mikus 2017",
                                "Output": "Organism|PeripheralVenousBlood|Midazolam|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Mikus 2017 - Midazolam control IV - Midazolam - IV - 2 mg - Plasma - agg. (n=12)",
                                    "Mikus 2017 - Midazolam control PO - Midazolam - PO - 4 mg - Plasma - agg. (n=12)"
                                ],
                                "Color": "#b2182b"
                            }
                        ]
                    }
                ]
            }
        ],
        "ComparisonTimeProfilePlots": [],
        "DDIRatioPlots": [],
        "PKRatioPlots": []
    },
    "Inputs": [
        {
            "Project": "Midazolam",
            "Name": "Midazolam",
            "Type": "Compound",
            "SectionReference": "final-input-parameters"
        },
        {
            "Project": "Midazolam",
            "Name": "Tablet (Dormicum)",
            "Type": "Formulation",
            "SectionReference": "final-input-parameters"
        }
    ],
    "Sections": [
        {
            "Reference": "introduction",
            "Title": "Introduction",
            "Content": "Content/Section1_Introduction.md"
        },
        {
            "Reference": "methods",
            "Title": "Methods",
            "Content": "Content/Section2_Methods.md",
            "Sections": [
                {
                    "Reference": "modeling-strategy",
                    "Title": "Modeling Strategy",
                    "Content": "Content/Section2.1_Modeling_Strategy.md"
                },
                {
                    "Reference": "data",
                    "Title": "Data",
                    "Content": "Content/Section2.2_Data.md"
                },
                {
                    "Reference": "model-parameters-and-assumptions",
                    "Title": "Model Parameters and Assumptions",
                    "Content": "Content/Section2.3_Model_Parameters_and_Assumptions.md"
                }
            ]
        },
        {
            "Reference": "results-and-discussion",
            "Title": "Results and Discussion",
            "Content": "Content/Section3_Results_and_Discussion.md",
            "Sections": [
                {
                    "Reference": "final-input-parameters",
                    "Title": "Final input parameters",
                    "Content": "Content/Input_table.md"
                },
                {
                    "Reference": "diagnostics-plots",
                    "Title": "Diagnostics Plots",
                    "Content": "Content/GOF_diagnostics.md"
                },
                {
                    "Reference": "ct-profiles",
                    "Title": "Concentration-Time Profiles",
                    "Content": "Content/Concentration_time_profiles.md",
                    "Sections": [
                        {
                            "Reference": "model-building",
                            "Title": "Model Building",
                            "Content": "Content/Concentration_time_profiles_building.md"
                        },
                        {
                            "Reference": "model-verification",
                            "Title": "Model Verification",
                            "Content": "Content/Concentration_time_profiles_verification.md"
                        }
                    ]
                }
            ]
        },
        {
            "Reference": "conclusion",
            "Title": "Conclusion",
            "Content": "Content/Section4_Conclusion.md"
        },
        {
            "Reference": "main-references",
            "Title": "References",
            "Content": "Content/References.md"
        }
    ],
    "Intro": [
        {
            "Path": "Content/titlepage.md"
        }
    ]
}